Intravenous Thrombolysis for Acute Ischemic Stroke

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 1 II, 2004, Pages

  Tomsick, Thomas A ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DUTEPLASE; FIBRINOLYTIC AGENT; HEPARIN;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DIGITAL SUBTRACTION ANGIOGRAPHY; DISABILITY; DOPPLER ECHOGRAPHY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HUMAN; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RECANALIZATION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 1642539072     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rvi.0000109203.06450.e3     Document Type: Review

References (84)

1. Frankel MR, Morgenstern LB, Kwiatkowski T, et al. Predicting prognosis after stroke: a placebo group analysis from the National Institutes of Neurologic Disorders and Stroke rtPA Trial. Neurology 2000; 55:952-959.
2. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993; 14:3-13.
3. Solis O, Roberson G, Taveras J, Mohr J, Pessin M. Cerebral angiography in acute cerebral infarction. Rev Interam Radiol 1977; 2:19-25.
4. Knepper L, Wehner JJ, Jungreis CA, Yonas H, Wechsler LR. Thromboembolic stroke due to acute ICA occlusion. In: Proceedings of the 23rd AHA International Conference on Stroke and Cerebral Circulation 1998; 45.
5. IMS Investigators. Interventional Management of Stroke: relationship of occlusive lesion to outcome (abstr). Stroke 2003; 34:278.
6. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32:78-86.
7. Furlan A, Higashida R, Weschler L. et al, for the PROACT II Investigators. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II Study-a randomized controlled trial. JAMA 1999; 282:2003-2011.
8. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001; 32:2821-2827.
9. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery stroke. Neurology 1992; 42:976-982.
10. Derex L, Tomsick TA, Brott TG, et al. Outcome of stroke patients without angiographic arterial occlusion. AJNR 2001; 21:685-690.
11. IMS Study Group. Late-breaking clinical trials: the Interventional Management of Stroke (IMS) Study-preliminary results. Presented at the 27th International Stroke Conference, February 9, 2002, San Antonio, Tex.
12. Alexandrov AV, Demchuk AM, Wein TH, Grotta JC. Yield of transcranial Doppler in acute cerebral ischemia. Stroke 1999; 30:1604-1609.
13. Demchuk AM, Burgin WS, Christou I, et al. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001; 32:89-93.
14. Saqqur M, Alexandrov A, Hill M, et al. Transcranial Doppler IMS criteria for rescue intraarterial thrombolysis: multicenter experience from the IMS Study (abstr). Stroke 2003; 34:267.
15. Alexandrov AV, Demchuk AM, Felberg RA, et al. High rate of complete recanalization and dramatic clinical recovery using tPA infusion when continuously monitored with 2-mhz transcranial Doppler monitoring. Stroke 2000; 31:610-614.
16. von Kummer R, Lamade UM, Forsting M, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery. AJNR 1994; 15:9-15.
17. von Kummer R, Holle R, Rosin L, et al. Does arterial recanalization improve outcome in carotid territory stroke? Stroke 1995; 26:581-587.
18. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632-640.
19. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23:641-645.
20. Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultra-early thrombolytic therapy. AJNR 1996; 17:79-85.
21. Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999; 53:S3-14.
22. Molina CA, Sabin JA, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with middle cerebral artery occlusion. Stroke 2002; 33:1551-1556.
23. Christou I, Alexandrov A, Burgin, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 2000; 31:1812-1816.
24. Lisboa RC, Jovanovic BD, Albers MJ. Analysis of safety and efficacy of intraarterial thrombolytic therapy in ischemic stroke. Stroke 2002; 33:2866-2871.
25. Lewandowski C, Frankel M, Tomsick T, et al, and the EMS Bridging Trial Investigators. Combined intravenous and intra-arterial r-tPA versus intraarterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30:2598-2605.
26. Tomsick T, Broderick JP, Pancioli AM, et al. Combined IV rtPA treatment in acute major stroke (abstr). Stroke 2002; 33:359.
27. Saito I, Segawa H, Shiokawa Y, Tanigoeli M, Tsutsumi K. Middle cerebral artery occlusion: correlation of computed tomography and angiography with clinical outcome. Stroke 1987; 18:863-868.
28. Schellinger PD, Jansen O, Fiebach JB, et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 2000; 31:1318-1328.
29. Schramm P, Schellinger PD, Fiebach JB, et al. Comparison of CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke 2002; 33:2426-2432.
30. Grotta JC, Welch KMA, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rtPA stroke trial. Stroke 2001; 32:661-668.
31. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59:862-867.
32. Brott T, Adams HP, Olinger CP, et al. Measurements of cerebral infarction: a clinical examination scale. Stroke 1989; 20:864-870.
33. Davalos A, Trueta J, Leira R, et al. The clinical DWI mismatch: a new diagnostic clue in the treatment of acute ischemic stroke (abstr). Stroke 2003; 34:254.
34. Woo D, Broderick JP, Kothari R, et al. Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? Stroke 1999; 30:2355-2359.
35. Nakajima M, Kimura K, Inoue T, et al. Relationship between angiographic findings and National Institutes of Health Stroke Scale Score in hyperacute ischemic stroke patients (abstr). Stroke 2003; 34:267.
36. Onundarson PT, Francis CW, Marder VJ. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med 1002; 120:121-128.
37. The NINDS t-PA Stroke Trial Investigators. Ultra-early administration of rt-PA in acute ischemic stroke within 3 hours of onset. N Engl J Med 1995; 333:1581-1587.
38. NINDS t-PA Study Group. Generalized efficacy of tPA for acute stroke. Stroke 1997; 28:2119-2125.
39. Brott T, Lu M, Kothari R, et al. Hypertension and its treatment in the NINDS rtPA stroke trial. Stroke 1998; 29:1504-1509.
40. NINDS Study Group. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 2000; 31:2912-2919.
41. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998; 50:883-890.
42. Lyden P. Further randomized controlled trials of tPA within 3 hours are required-not. Stroke 2001; 32:2209-2210.
43. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ 2002; 324:723-729.
44. Haley EC, Lewandowski C, Tilley BC, NINDS rtPA Study Group. Myths regarding the NINDS rtPA Stroke Trial: setting the record straight. Ann Emerg Med 1997; 30:676-682.
45. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 2000; 283:1145-1150.
46. Hacke W, Bluhmki E, Steiner T, et al. Dichotomized efficacy end points and global end point analysis applied to the ECASS intention-to-treat data set: analysis of ECASS I. Stroke 1998; 29:2073-2075.
47. Busse O, von Kummer R, Toni A, et al. Thrombolysis does not prevent subcortical infarction (abstr). Stroke 1996; 27:176.
48. Hacke W, Kaste M, Fieschi C, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998; 352:1245-1251.
49. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS study-a randomized controlled trial. JAMA 1999; 282:2019-2026.
50. Broderick J, Lu M, Kothari R, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000; 31:2335-2341.
51. Ringleb PA, Schellinger PD, Schranz C, Hacke W. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke. Stroke 2002; 33:1437-1441.
52. Brott T. Summary of IV Emergency Stroke Trials: past and future directions. In: Proceedings of the 41st Annual Meeting of the ASNR. Washington, DC: American Society of Neuroardiology, 2003; 203.
53. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers. Stroke 2001; 32:1061-1068.
54. Katzan IL, Silla CA, Furlan AJ. Community use of intravenous tissue plasminogen activator for acute stroke. Stroke 2001; 32:861-864.
55. Toni D, Fiorelli M, Bastianello S, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996; 46:341-345.
56. Levy DA, Brott TG, Haley EC, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25:291-297.
57. NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28:2109-2118.
58. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001; 32:1330-1334.
59. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct. Stroke 1999; 30:2280-2284.
60. Grotta JC, Chiu D, Lu M, et al. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999; 30:1528-1533.
61. Uchino K, Molina CA, Saqqur M, et al. Likelihood of early recanalization with intravenous tPA and its predictors: a multicenter transcranial Doppler study. Stroke 2003; 34:247.
62. Jones TH, Morawetz RB, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981; 54:773-782.
63. Zivin J. Factors determining the therapeutic window for stroke. Neurology 1998; 50:559-603.
64. Neumann-Haeffelin T, Wittsack HJ, Wenserski F, et al. Diffusion- and perfusion-weighted MRI: the DWI/PWI mismatch region in acute stroke. Stroke 1999; 30:1591-1597.
65. Karonen JO, Vanninen RL, Liu Y, et al. Combined diffusion and perfusion MRI with correlation to single-photon emission CT in acute ischemic stroke. Stroke 1999; 30:1583-1590.
66. Darby DO, Barber PA, Gerraty, et al. Pathophysiologic topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 1999; 30:2043-2053.
67. Oppenheim C, Grandin C, Samson Y, et al. Is there an apparent diffusion coefficient threshold in predicting tissue viability in hyperacute stroke. Stroke 2001; 32:2486-2491.
68. Tremwell M, Saver JL, Alger JR, et al. Frequency and determinants of pseudonormalization and true normalization identified with diffusion MRI following thrombolysis.
69. Marler J, Tilley BC, Mei L, et al. Earlier treatment associated with better outcome in the NINDS tPA trial (abstr). Stroke 1999; 30:244.
70. Kanter D, Kothari R, Pancioli A, et al. The greater Cincinnati tPA experience after the NINDS trial: does a longer time to treatment within the current 3-hour window reduce efficacy (abstr)? Stroke 1999; 30:244.
71. Widermuth S, Knauth M, Brandt T, et al. Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke. Stroke 1998; 29:935-938.
72. Koenig M, Klotz E, Luka B, et al. Perfusion CT of the brain: diagnostic approach for early detection of ischemic stroke. Radiology 1998; 209:85-93.
73. Reichenbach JR, Rother J, Mentzel LJ, et al. Acute stroke evaluated by time-to-peak mapping during initial and early follow-up perfusion CT studies. AJNR 1999; 20:1842-1850.
74. Mayer TE, Hamann GF, Baranczyk J, et al. Dynamic CT perfusion imaging of acute stroke. AJNR 2000; 21:1441-1449.
75. Albers G. Expanding the window for thrombolytic therapy in acute stroke: the potential role of acute MRI for patient selection. Stroke 1999; 30:2230-2237.
76. Sunshine JL, Tarr RW, Lanzieri C, et al. Hyperacute stroke: ultrafast MR imaging to triage patients prior to therapy. Radiology 1999; 212:325-332.
77. Keir SL, Wardlaw JM. Systematic review of diffusion and perfusion imaging in acute ischemic stroke. Stroke 2000; 31:2723-2731.
78. Scramm P, Scellinger PD, Fiebach JB, et al. Comparison of CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke 2002; 33:2426-2432.
79. Rother J, Scellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke < 6 hours. Stroke 2002; 33:2438-2445.
80. Wintermark M, Reichardt M, Cuisinaire O, et al. Comparison of admission perfusion computed tomography and qualitative diffusion and perfusion weighted magnetic resonance imaging in acute stroke patients. Stroke 2002; 33:2025-2031.
81. Ezzeddine MA, Lev MH, McDonald CT, et al. CT angiography with whole brain perfused blood volume imaging. Stroke 2002; 33:959-966.
82. Bogousslavsky J, Reichart M, Wintermark M, et al. Pre-thrombolysis cerebral blood flow and penumbra assessment within 3 hours of ischemic stroke: a perfusion-CT, MRI controlled, prospective study. Stroke 2003; 34:239.
83. Kuelkens S, Schwark C, Schellinger, et al. Systemic thrombolysis in ischemic stroke 3 to 6 hours after onset of symptoms using an MR based algorithm. Stroke 2003; 34:247.
84. Schellinger PD, Jansen O, Fiebach JB, et al. Feasability and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. AJNR 2000; 21:1184-1189.